# Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

> **NCT06343376** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography
- **BIOLOGICAL:** EGFRt/19-28z/IL-12 CAR T-lymphocytes
- **DRUG:** Fludarabine Phosphate
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06343376
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-26
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-01-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Manufacturing issues
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06343376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06343376, "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06343376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*